MDNAF — Medicenna Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Medicenna Therapeutics Announces Pricing Of Marketed Offering Of Units
Brief: Medicenna Announces Offering Of Units
Brief: Medicenna Therapeutics Says Il4r Patients Survived Twice As Long As Approved Treatments
Brief: Medicenna Therapeutics QTRLY Loss Per Share $0.05
Brief: Medicenna Selects Its Lead Immuno-Oncology Clinical Candidate, Mdna19, From Its Il-2 Superkine Platform
Brief: Medicenna Therapeutics Says Funds Available Sufficient To Complete Mdna55 Phase 2b Clinical Study
Brief: Medicenna Presents New Preclinical Results For Its Il-2 Superkine Platform, Mdna109
Brief: Medicenna Presents Preliminary Top-Line Clinical Results From Their Phase 2B Trial Of Mdna55 In Recurrent Glioblastoma
Brief: Medicenna Therapeutics Presents Clinical Validation Of IL4 Receptor As A Biomarker For MDNA55 In Recurrent Glioblastoma
Brief: Medicenna Therapeutics Reports Q3 Loss Per Share Of C$0.07
Brief: Medicenna Presents Promising Clinical Data From Phase 2B Recurrent Glioblastoma Trial Of Mdna55
Brief: Medicenna Presents Promising Clinical Data From Phase 2B Recurrent Glioblastoma Trial Of MDNA55
Brief: Medicenna Shows Promising Pre-Clinical Results In Solid Tumor Models With Its Il-2 Superkine, Mdna109
Brief: Preliminary Results On MDNA55 And MDNA109 To Be Presented At The Immuno-Oncology 360° Conference
Brief: Medicenna Therapeutics Corp Receives US$1.2 Mln Non-Dilutive Grant Payment
Brief: Medicenna Therapeutics Q2 Loss Per Share C$0.04
Brief: Medicenna Announces Marketed Offering Of Units
Brief: Medicenna Provides Positive Interim Update From Phase 2B Trial Of MDNA55 In Recurrent Glioblastoma
Brief: Medicenna Reports Q1 Loss Per Share C$0.04